

July 28, 2025

Company Name: **Veritas In Silico Inc.**
Representative: Shingo NAKAMURA,
Representative Director and CEO
Listed on: TSE Growth
Stock Ticker Code: 130A
Contact Person: Tsuneo GODA,
Executive Officer, General Manager,
Corporate Planning Division
Email: ir@veritasinsilico.com

Patent owned by Veritas In Silico receives Notice of Allowance in the U.S.

Veritas In Silico Inc. (hereafter referred to as “the Company”) has announced that one of its patents, "METHOD FOR SCREENING COMPOUND FOR CONTROLLING RNA FUNCTION " has been scheduled to be authorized as a patent in the United States.

The patent application has been approved by the United States Patent and Trademark Office (“USPTO”) and the Company has received a Notice of Allowance*.

- Title of Invention: METHOD FOR SCREENING COMPOUND FOR CONTROLLING RNA FUNCTION
- Application Number: US16/980,245
(International Application Number: PCT/JP2019/010571)
- Patent Holder: Veritas In Silico Inc.

* USPTO has evaluated this patent and confirmed that it is worthy of protection. The patent rights take effect once the company pays the Issue Fee.

The patent covers the analysis of substructures inherent in target mRNAs and their existence probabilities, the identification of substructures with existence probabilities appropriate as drug targets, and screening methods using the identified substructures. The patent is the foundation of the Company's proprietary drug discovery platform, ibVIS®.

The Company has already obtained patent rights for this technology in Japan on October 21, 2020, and in Europe on January 1, 2025 (for details on the acquisition of patent rights in Europe, please refer to the announcement dated December 30, 2024, titled “[Patent owned by Veritas In Silico to Become Effective in Europe](#)”).

With the granting of the patent in the U.S., this technology has been authorized in major countries and its progressiveness and novelty shall be widely recognized. Exclusive use rights for the Company have been guaranteed on an international level at the same time. The Company is to advance its technological development to enhance its superiority.

The patent acquisition will have a negligible impact on its business performance. The Company is certain that it will contribute to accelerating the globalization of its joint drug discovery research.

For Further Information, Contact:

- Veritas In Silico Website Inquiry Form : <https://www.veritasinsilico.com/en/contact/>